Repurposing FDA-approved sulphonamide carbonic anhydrase inhibitors for treatment of Neisseria gonorrhoeae

Neisseria gonorrhoeae is a high-priority pathogen of concern due to the growing prevalence of resistance development against approved antibiotics. Herein, we report the anti-gonococcal activity of ethoxzolamide, the FDA-approved human carbonic anhydrase inhibitor. Ethoxzolamide displayed an MIC(50,)...

Descripción completa

Detalles Bibliográficos
Autores principales: Abutaleb, Nader S., Elhassanny, Ahmed E. M., Nocentini, Alessio, Hewitt, Chad S., Elkashif, Ahmed, Cooper, Bruce R., Supuran, Claudiu T., Seleem, Mohamed N., Flaherty, Daniel P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Research Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8667909/
https://www.ncbi.nlm.nih.gov/pubmed/34894972
http://dx.doi.org/10.1080/14756366.2021.1991336

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8667909/
https://www.ncbi.nlm.nih.gov/pubmed/34894972
http://dx.doi.org/10.1080/14756366.2021.1991336

Ejemplares similares